Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the medical research council AML15 trial

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3360-3368

  Burnett, Alan K ^a   Russell, Nigel H ^b   Hills, Robert K ^a   Hunter, Ann E ^c   Kjeldsen, Lars ^h   Yin, John ^d   Gibson, Brenda E S ^e   Wheatley, Keith ^f   Milligan, Donald ^g  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^h Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILD; COMPARATIVE EFFECTIVENESS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; NEWBORN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGE; ANALOGS AND DERIVATIVES; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84894365265     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.4874     Document Type: Article

References (17)

1. Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
2. Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27: 5397-5403, 2009
3. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
4. Hann IM, Stevens RF, Goldstone AH, et al: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia: Results of the Medical Research Council's 10th AML Trial (MRC AML 10) - Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89:2311-2318, 1997
5. Büchner T, Schlenk RF, Schaich M, et al: Acute myeloid leukemia (AML): Different treatment strategies versus a common standard arm - Combined prospective analysis by the German AML Intergroup. J Clin Oncol 30:3604-3610, 2012
6. Estey E, Thall P, Andreeff M, et al: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671-678, 1994
7. Parker JE, Pagliuca A, Mijovic A, et al: Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol 99:939-944, 1997
8. Clavio M, Gatto S, Beltrami G, et al: Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant: A feasable and effective therapeutic strategy for de novo AML patients. J Exp Clin Cancer Res 21:481-487, 2002
9. Burnett AK, Hills RK, Milligan D, et al: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 Trial. J Clin Oncol 29:369-377, 2011
10. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
11. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendation of the International Working Group for diagnosis standardization, of response criteria treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003
12. Löwenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361: 1235-1248, 2009
13. Lee JH, Joo YD, Kim H, et al: A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118:3832-3841, 2011
14. Ohtake S, Miyawaki S, Fujita H, et al: Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 Study. Blood 117:2358-2365, 2011
15. Holowiecki J, Grosicki S, Giebel S, et al: Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: A multicenter, randomized phase III Study. J Clin Oncol 30:2441-2448, 2012
16. Castaigne S, Pautas C, TerréC, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 379:1508-1516, 2012
17. Burnett AK, Russell NH, Hills RK, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924-3931, 2012